Skye Bioscience, Inc.

NasdaqGM:SKYE Voorraadrapport

Marktkapitalisatie: US$168.7m

Skye Bioscience Beheer

Beheer criteriumcontroles 2/4

Skye Bioscience's CEO is Punit Dhillon, appointed in Aug 2020, has a tenure of 4.25 years. total yearly compensation is $1.81M, comprised of 24.9% salary and 75.1% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $244.81K. The average tenure of the management team and the board of directors is 2.5 years and 0.7 years respectively.

Belangrijke informatie

Punit Dhillon

Algemeen directeur

US$1.8m

Totale compensatie

Percentage CEO-salaris24.9%
Dienstverband CEO4.3yrs
Eigendom CEO0.1%
Management gemiddelde ambtstermijn2.5yrs
Gemiddelde ambtstermijn bestuurless than a year

Recente managementupdates

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11
Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Analyse CEO-vergoeding

Hoe is Punit Dhillon's beloning veranderd ten opzichte van Skye Bioscience's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$2mUS$450k

-US$38m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$668kUS$433k

-US$19m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

-US$9m

Dec 31 2021US$900kUS$400k

-US$9m

Sep 30 2021n/an/a

-US$8m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$615kUS$160k

-US$7m

Sep 30 2020n/an/a

-US$207k

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

US$13m

Dec 31 2019US$65kn/a

US$1m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$26m

Dec 31 2018US$82kn/a

-US$19m

Compensatie versus markt: Punit's total compensation ($USD1.81M) is about average for companies of similar size in the US market ($USD1.48M).

Compensatie versus inkomsten: Punit's compensation has increased whilst the company is unprofitable.

CEO

Punit Dhillon (44 yo)

4.3yrs

Tenure

US$1,807,338

Compensatie

Mr. Punit S. Dhillon, BA, has been Chief Executive Officer of Skye Bioscience, Inc. since August 10, 2020. Mr. Dhillon serves as Chair of Skye Bioscience, Inc. until October 25, 2024. He served as Principa...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Punit Dhillon
President4.3yrsUS$1.81m0.15%
$ 244.8k
Kaitlyn Arsenault
Chief Financial Officer3.1yrsUS$1.27m0.13%
$ 220.4k
Christopher Twitty
Chief Scientific Officer1.9yrsgeen gegevensgeen gegevens
Tu Diep
Chief Development Officerno datageen gegevens0.0088%
$ 14.8k
Puneet Arora
Chief Medical Officerless than a yeargeen gegevensgeen gegevens

2.5yrs

Gemiddelde duur

43.5yo

Gemiddelde leeftijd

Ervaren management: SKYE's management team is considered experienced (2.5 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Punit Dhillon
President6.8yrsUS$1.81m0.15%
$ 244.8k
Paul Grayson
Independent Chairman of the Board1.3yrsUS$1.25m0.077%
$ 129.7k
Andrew Schwab
Director1.3yrsUS$74.08k0%
$ 0
Louis Aronne
Member of Clinical & Scientific Advisory Boardless than a yeargeen gegevensgeen gegevens
Annalisa Lisa Jenkins
Independent Directorless than a yeargeen gegevens0%
$ 0
Karen Smith
Directorless than a yeargeen gegevens0%
$ 0
Deborah Charych
Independent Director1.8yrsUS$102.28k0%
$ 0
Rekha Kumar
Member of Clinical & Scientific Advisory Boardless than a yeargeen gegevensgeen gegevens
Lee Kaplan
Member of Clinical & Scientific Advisory Boardless than a yeargeen gegevensgeen gegevens
Beverly Tchang
Member of Clinical & Scientific Advisory Boardless than a yeargeen gegevensgeen gegevens
Marcus Goncalves
Member of Clinical & Scientific Advisory Boardless than a yeargeen gegevensgeen gegevens

0.7yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: SKYE's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.